A5022444628- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Traffic control and management
- Traffic Prediction and Management Techniques
- Traffic and Road Safety
- Estrogen and related hormone effects
- Human-Automation Interaction and Safety
- Protease and Inhibitor Mechanisms
- Pulsars and Gravitational Waves Research
- Cancer Immunotherapy and Biomarkers
- Autonomous Vehicle Technology and Safety
- Esophageal Cancer Research and Treatment
- Medical Imaging Techniques and Applications
- Cosmology and Gravitation Theories
- Peptidase Inhibition and Analysis
- Breast Lesions and Carcinomas
- Radiomics and Machine Learning in Medical Imaging
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Relativity and Gravitational Theory
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
Deutsches Archäologisches Institut, Zentrale
2016-2025
German Inflammatory Bowel Diseases Study Group
2011-2024
Women‘s Healthcare Group
2013-2023
Ansys (Germany)
2012-2023
Champalimaud Foundation
2021
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2019
Medizinische Hochschule Hannover
2016-2019
Hospital Clínic de Barcelona
2019
Ludwig-Maximilians-Universität München
2013-2017
Krankenhaus vom Roten Kreuz
2017
Background: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion metastasis. High levels of both uPA PAI-1 are associated with poor prognosis breast cancer patients. To confirm the prognostic value primary cancer, we reanalyzed individual patient data provided by members European Organization for Research Treatment Cancer–Receptor Biomarker Group (EORTC-RBG). Methods: The study included 18 datasets involving 8377 During follow-up (median...
The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only few prospective outcome results have been available so far. In the phase III PlanB trial, RS was prospectively used to define subset of patients who received endocrine therapy. We present 3-year data and concordance analysis (among biomarkers/RS).Central tumor bank established from (intermediate high-risk, locally human epidermal growth factor...
The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating prognostic value RS, Ki-67, and other traditional clinicopathological parameters. A central tumour bank was prospectively established within PlanB. Following an amendment, hormone receptor (HR)+ , RS ≤ 11 were...
To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) guide systemic in early breast cancer.Baseline postendocrine Ki67 (Ki67post) were evaluated centrally. In trial, all patients received exclusively ET: with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved nodes) entered control arm if RS...
Purpose Human epidermal growth factor receptor 2 (HER2)–positive/hormone (HR)–positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little known about the efficacy of combination endocrine therapy (ET) trastuzumab or potent antibody-cytotoxic, anti-HER2 compound emtansine (T-DM1) without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted...
PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment human epidermal growth factor receptor 2–negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more following: pT greater than 2, grade 2 3, high urokinase-type plasminogen activator/plasminogen activator...
Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results higher pCR rates uncertain survival impact. We evaluated gemcitabine a backbone as short 12-week A-free focus on early response.Patients TNBC (estrogen receptor/progesterone receptor < 1%, human epidermal growth factor 2-negative,...
Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial continuous improvement of outcome has been achieved over the past decades. Response to therapy currently not considered procedure. ADAPT one first new generation (neo)adjuvant trials dealing with individualization early breast cancer aims...
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
A recent study presented first evidence that a single nucleotide polymorphism (SNP) at codon 388 of fibroblast growth factor receptor 4 (FGFR4) gene, causing transmembrane domain missense mutation (Gly388Arg), is associated with disease outcome in node-positive breast cancer. This article addresses the clinical relevance this SNP, FGFR4 genotype, phenotype, and HER2 regarding patient influence adjuvant systemic therapy substantial primary cancer collective (n = 372; median follow-up, 94.5...
Abstract Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data multiple international trials of presurgical in order provide guidance on identification who may insufficiently endocrine-sensitive tumors and should be prioritised for early or chemotherapy rather than NeoET aftermath pandemic safety when surgical activity needs prioritized. For postmenopausal patients, our...
Introduction: Innovations in 3D spatial technology and augmented reality imaging driven by digital high-tech industrial science have accelerated experimental advances breast cancer the development of medical procedures aimed to reduce invasiveness. Presentation case: A 57-year-old post-menopausal woman presented with screen-detected left-sided cancer. After undergoing all staging pre-operative studies patient was proposed for conservative surgery tumor localization. During surgery, an...
Abstract Background Anthracycline/cyclophosphamide-taxane-containing chemotherapy (AC-T) is the standard of care in adjuvant treatment HER2-negative early breast cancer (EBC), but recent studies suggest omission anthracyclines for reduced toxicity without compromising efficacy. Methods Based on individual patient data ( n = 5924) pooled from randomised Phase III trials PlanB and SUCCESS C, we compared disease-free survival (DFS) overall (OS) between intermediate to high-risk EBC-patients...
Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective the hormone status. Trastuzumab-emtansine (T-DM1), antibody-drug conjugate, highly effective HER2+ EBC; however, no survival data are available for de-escalated conjugate-based neoadjuvant therapy without conventional chemotherapy.In WSG-ADAPT-TP (ClinicalTrials.gov identifier: NCT01779206) phase II trial, 375 centrally reviewed patients with...
PURPOSE: A strong prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor type 1 (PAI-1) as individual factors is well established in breast cancer. The improvement clinical risk assessment gained by combining these evaluated here. PATIENTS AND METHODS: uPA PAI-1 levels were prospectively measured enzyme-linked immunosorbent assay tumor tissue extracts 761 patients with primary RESULTS: In the clinically important subgroup node-negative without adjuvant systemic...
Abstract Purpose: Complete or partial loss of dihydropyrimidine dehydrogenase (DPD) function has been described in cancer patients with intolerance to fluoropyrimidine drugs like 5-fluorouracil (5-FU) Xeloda. The intention this population study is assess and evaluate gene variations the entire coding region (DPYD), which could be implicated DPD malfunction. Experimental Design: A cohort 157 individuals was genotyped by denaturing high-performance liquid chromatography; 100 these genotypes...
Purpose: The independent clinical relevance of invasion factors urokinase-type plasminogen activator (uPA)/PAI-1 and HER2 status was evaluated in lymph node-negative breast cancer patients (N = 118) without adjuvant systemic therapy after long-term follow-up more than 10 years (median, 126 months). Patients Methods: Levels uPA its inhibitor PAI-1 were prospectively measured by enzyme-linked immunosorbent assay primary tumor tissue extracts. gene amplification (HER2_AMP) fluorescence situ...